UA105629C2 - Похідні арилсульфоніл піразолін карбоксамідину як антагоністи 5-нт6 - Google Patents

Похідні арилсульфоніл піразолін карбоксамідину як антагоністи 5-нт6

Info

Publication number
UA105629C2
UA105629C2 UAA201012295A UAA201012295A UA105629C2 UA 105629 C2 UA105629 C2 UA 105629C2 UA A201012295 A UAA201012295 A UA A201012295A UA A201012295 A UAA201012295 A UA A201012295A UA 105629 C2 UA105629 C2 UA 105629C2
Authority
UA
Ukraine
Prior art keywords
disorders
compounds
disorder
antagonists
disease
Prior art date
Application number
UAA201012295A
Other languages
English (en)
Russian (ru)
Inventor
Арнольд ван Левезійн
Баккер Воутер І. Івема
Аксель Стойт
Агата А.М. Ренсінк
Дженніфер Венхорст
Мартіна А.В. ван дер Нойт
Мартін де Хаан
Корнеліс Г. Крузе
Original Assignee
Еббот Хелскеа Продактс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еббот Хелскеа Продактс Б.В. filed Critical Еббот Хелскеа Продактс Б.В.
Publication of UA105629C2 publication Critical patent/UA105629C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Даний винахід стосується похідних арилсульфоніл піразолін карбоксамідину як антагоністів рецепторів 5-НТ6, способів одержання цих сполук та нових проміжних сполук, корисних для їх синтезу. Винахід також стосується застосування таких сполук та композицій, зокрема введення їх пацієнтам, для досягнення терапевтичної дії при лікуванні хвороби Паркінсона, хореї Гантінгтона, шизофренії, бентежності, депресії, маніакальної депресії, психозів, епілепсії, нав'язливих компульсивних розладів, розладів настрою, мігрені, хвороби Альцгеймера, пов'язаного з віком зниження пізнавальної функції, м'яких когнітивних погіршень, розладів сну, розладів харчування, анорексії, булімії, розладів надмірного харчування, нападів паніки, акатизії, розладів гіперактивності з дефіцитом уваги, розладів дефіциту уваги, синдрому відміни при залежності від кокаїну, етанолу, нікотину або бензодіазепінів, болю, розладів, пов'язаних з травмою спинного мозку або пошкодженням голови, гідроцефалії, функціональних розладів шлунка, синдрому подразненого кишечника, опасистості та діабету 2 типу. Сполуки мають загальну формулу (1): EMBED ISIS/Draw Sketch , (1) де радикали мають значення, наведені у описі.
UAA201012295A 2008-03-18 2009-03-17 Похідні арилсульфоніл піразолін карбоксамідину як антагоністи 5-нт6 UA105629C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3746308P 2008-03-18 2008-03-18
EP08152873 2008-03-18
PCT/EP2009/053133 WO2009115515A1 (en) 2008-03-18 2009-03-17 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists

Publications (1)

Publication Number Publication Date
UA105629C2 true UA105629C2 (uk) 2014-06-10

Family

ID=39639064

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201012295A UA105629C2 (uk) 2008-03-18 2009-03-17 Похідні арилсульфоніл піразолін карбоксамідину як антагоністи 5-нт6

Country Status (29)

Country Link
US (3) US8563723B2 (uk)
EP (2) EP2610247B1 (uk)
JP (1) JP5504252B2 (uk)
KR (1) KR101623357B1 (uk)
CN (2) CN102036967B (uk)
AR (1) AR070898A1 (uk)
AU (1) AU2009226956C1 (uk)
BR (1) BRPI0908738A8 (uk)
CA (1) CA2717922A1 (uk)
CO (1) CO6290679A2 (uk)
CR (1) CR11742A (uk)
DK (2) DK2610247T3 (uk)
DO (2) DOP2010000276A (uk)
EA (1) EA023176B1 (uk)
EC (1) ECSP10010476A (uk)
ES (2) ES2565184T3 (uk)
HK (2) HK1152708A1 (uk)
IL (1) IL207846A0 (uk)
MX (1) MX2010010299A (uk)
MY (1) MY155318A (uk)
NZ (1) NZ587743A (uk)
PH (1) PH12013502376B1 (uk)
PL (2) PL2610247T3 (uk)
PT (1) PT2610247T (uk)
SG (1) SG183688A1 (uk)
TW (1) TWI557110B (uk)
UA (1) UA105629C2 (uk)
WO (1) WO2009115515A1 (uk)
ZA (1) ZA201006272B (uk)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079935A1 (es) 2010-01-29 2012-02-29 Abbott Healthcare Products Bv Sintesis de derivados de pirazolin carboxamidina sustituida
MX356486B (es) * 2011-08-15 2018-05-30 Univ Utah Res Found Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa.
SG11201503562PA (en) 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
DK2920165T3 (en) * 2012-11-16 2017-01-16 Bristol Myers Squibb Co Dihydropyrazol-GPR40-MODULATORS
CN104918935B (zh) * 2012-11-16 2017-07-28 百时美施贵宝公司 二氢吡唑gpr40调节剂
CN106660968B (zh) * 2014-05-09 2020-02-07 美国政府(由卫生和人类服务部的部长所代表) 吡唑衍生物及其作为大麻素受体介体的用途
US10385040B2 (en) 2014-08-12 2019-08-20 Loyola University Of Chicago Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN107460160A (zh) * 2017-08-23 2017-12-12 世贸天阶制药（江苏）有限责任公司 一种cho细胞无血清培养基
US10879709B2 (en) 2018-05-31 2020-12-29 National Taipei University Of Technology Power management system and operating method thereof
MX2022004367A (es) 2019-10-09 2022-05-06 Bayer Ag Nuevos compuestos de heteroarilo-triazol como pesticidas.
CA3185968A1 (en) 2020-07-13 2022-01-20 Tony Lahoutte Antibody fragment against folr1
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429762A1 (en) * 2001-09-21 2004-06-23 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
AR062907A1 (es) * 2006-09-22 2008-12-17 Solvay Pharm Bv Derivados de sulfonilpirazol y sulfonilpirazolincarboxamidina como antagonistas de 5-ht6

Also Published As

Publication number Publication date
ES2577867T3 (es) 2016-07-19
US8563723B2 (en) 2013-10-22
CN102036967A (zh) 2011-04-27
DOP2010000276A (es) 2010-11-15
CO6290679A2 (es) 2011-06-20
CN104003937A (zh) 2014-08-27
US20150051239A1 (en) 2015-02-19
PH12013502376A1 (en) 2015-01-12
EA023176B1 (ru) 2016-05-31
US8901108B2 (en) 2014-12-02
KR20100136504A (ko) 2010-12-28
IL207846A0 (en) 2010-12-30
DK2610247T3 (en) 2016-06-13
NZ587743A (en) 2012-06-29
US20140011775A1 (en) 2014-01-09
ECSP10010476A (es) 2010-10-30
ES2565184T3 (es) 2016-04-01
TW200942519A (en) 2009-10-16
BRPI0908738A2 (pt) 2017-06-13
ZA201006272B (en) 2011-05-25
CA2717922A1 (en) 2009-09-24
WO2009115515A1 (en) 2009-09-24
AU2009226956A8 (en) 2010-09-23
BRPI0908738A8 (pt) 2017-10-10
TWI557110B (zh) 2016-11-11
MY155318A (en) 2015-09-30
EP2610247A1 (en) 2013-07-03
EA201071083A1 (ru) 2011-04-29
AU2009226956B2 (en) 2013-05-23
PL2265589T3 (pl) 2016-06-30
US9126942B2 (en) 2015-09-08
CN102036967B (zh) 2014-10-15
JP2011517443A (ja) 2011-06-09
PH12013502376B1 (en) 2015-01-12
CR11742A (es) 2011-03-03
PL2610247T3 (pl) 2017-02-28
JP5504252B2 (ja) 2014-05-28
HK1201823A1 (en) 2015-09-11
EP2610247B1 (en) 2016-05-25
EP2265589A1 (en) 2010-12-29
MX2010010299A (es) 2010-12-15
US20110046171A1 (en) 2011-02-24
AU2009226956A1 (en) 2009-09-24
PT2610247T (pt) 2016-07-07
AU2009226956C1 (en) 2014-03-06
DOP2010000277A (es) 2011-01-31
EP2265589B1 (en) 2016-01-27
AR070898A1 (es) 2010-05-12
SG183688A1 (en) 2012-09-27
HK1152708A1 (en) 2012-03-09
DK2265589T3 (en) 2016-03-21
KR101623357B1 (ko) 2016-05-23

Similar Documents

Publication Publication Date Title
UA105629C2 (uk) Похідні арилсульфоніл піразолін карбоксамідину як антагоністи 5-нт6
MX2009003183A (es) Derivados de sulfonilpirazolincarboxamidina como antagonistas de 5-ht6.
DE69705608D1 (de) Tropanderivate, deren herstellung und verwendung
MX2009003801A (es) Aminometil-4-imidazoles.
MX2007004230A (es) Compuestos de tienopiridinona y metodos de tratamiento.
MX2009005509A (es) 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
DE602007013275D1 (de) Verbindungen mit kombinierten cannabinoid-cb1-antagonismus und acetylcholinesterasehemmung
ZA200810031B (en) 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use for the manufacture of medicaments
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
NZ592563A (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
TW200833327A (en) 4-imidazolines as TAAR's ligands
MX363632B (es) Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
MX2009007405A (es) Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina.
UA98122C2 (uk) Похідні сульфонілпіразол та сульфонілпіразолон карбоксамідину як антагоністи рецепторів 5-ht6
TH127978A (th) อนุพันธ์เอริลซัลโฟนิลไพราโซลีนคาร์บอกซามิดีนในฐานะ 5-ht6 แอนตะโกนิสท์
MX2010008239A (es) 2-aminoquinolinas.
EA200970672A1 (ru) Соединения с комбинацией каннабиноид-свантагонизма и ингибирования обратного захвата серотонина
MX2009006889A (es) Compuestos con una combinacion de antagonismo de cannabinoide-receptor cannabinoide subtipo 1 e inhibicion de acetilcolinesterasa.
TH101181A (th) อนุพันธ์ซัลโฟนิลไพราโซลและซัลโฟนิลไพราโซลีน คาร์บอกซามิดีนเป็น 5-ht6 แอนทาโกนิสท์
TH101181B (th) อนุพันธ์ซัลโฟนิลไพราโซลและซัลโฟนิลไพราโซลีน คาร์บอกซามิดีนเป็น 5-ht6 แอนทาโกนิสท์
WO2003014114A3 (en) Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TH107949A (th) อนุพันธ์ใหม่ของ (บริดเจด พิเพอร์แอซินิล)-1-แอลคาโนน และการใช้มันเป็นตัวยับยั้ง p75